Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Regenerative Graft Company Locate Bio Secures £10m Funding Round

Executive Summary

The money will be used to further clinical research for its innovative, drug releasing, bone grafting products.

You may also be interested in...



Locate Bio Joins UK Biomaterials Innovators Addressing Unmet Orthopedic Surgery Needs

Since its September 2021 $13m (£10m) funding round, Locate Bio has continued the development of its range of orthobiologics focused on improving outcomes from orthopedic surgery.

Blue Sky Thinking: CEOs, Analysts Offer Some Thoughts On 2022

As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.

Execs On The Move: June 2022

An interactive view of medtech executive changes from the month of June.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel